Previous 10 | Next 10 |
Results indicate significant decrease in cocaine craving in a sub-group that received the treatment TEL AVIV, Israel, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat d...
The pre-funded warrants were issued as part of the $10 million private placement from June 2022 TEL AVIV, Israel, Aug. 19, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focus...
Clinical-stage pharmaceutical company SciSparc ( NASDAQ: SPRC ) said it will deposit $1M in escrow intending to acquire American food supplements and cosmetics brand. The company has signed a non-binding letter of intent with Merhavit M.R.M Holding and Manag...
The Company has signed an escrow agreement following the signing of a non-binding letter of intent and will be deposit a $1 .0 million as an initial intention to enter into a definitive acquisition agreement TEL AVIV, Israel, Aug. 18, 2022 (GL...
A specialty clinical-stage pharmaceutical company SciSparc ( NASDAQ: SPRC ) signed a letter of intent with Merhavit M.R.M Holding and Management to acquire from it its rights to purchase, a top-seller Amazon.com account and American food supplements and cos...
The Letter of Intent contemplates the purchasing of a brand, trademark and Amazon.com seller account, a management agreement, a U.S. distribution agreement and an option to expand to new territories TEL AVIV, Israel, Aug. 15, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (...
Patent extends protection for SciSparc’s novel compounds and methods a lready granted i n the U . S . , Australia a nd Japan TEL AVIV, Israel, Aug. 12, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a spe...
The trial's objectives are to evaluate the safety, tolerability and efficacy of SciSparc's SCI-210 in children and adolescents with ASD TEL AVIV, Israel, Aug. 08, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutic...
The addition of a U . S . site will allow SciSparc to accelerate trial recruitment and further development of novel treatments for patients in need TEL AVIV, Israel, Aug. 01, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty...
Israel-based SciSparc ( NASDAQ: SPRC ) on Friday said it had started the process of preparing for an investigational new drug application for its phase 2b trial evaluating its SCI-110 drug candidate for Tourette Syndrome. As part of the process, the company will expand the...
News, Short Squeeze, Breakout and More Instantly...
SciSparc Ltd. Company Name:
SPRC Stock Symbol:
NASDAQ Market:
TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, ann...
PRA Group Inc. (PRAA) is expected to report $-0.15 for Q1 2024 Bowman Consulting Group Ltd. (BWMN) is expected to report $-0.04 for Q1 2024 Noble Corporation plc A (NE) is expected to report $0.56 for Q1 2024 Velo3D Inc. (VLD) is expected to report for Q3 2024 Axon Enterprise Inc....
SciSparc Ltd. (SPRC) is expected to report for quarter end 2023-12-31